Endovascular therapy for acute ischemic stroke continues to evolve to improve both efficacy and safety. In the late 1990s, intra-arterial chemical thrombolysis with prourokinase was shown to be effective in achieving partial recanalization and improving clinical outcome, in comparison with intra-arterial heparin administration. However, this was at the expense of an increase in the rate of symptomatic intracranial hemorrhage to 10%. To improve the rate of recanalization, expand the time window, and reduce the risk of symptomatic intracranial hemorrhage, mechanical thrombectomy was introduced, with initial approval of the Merci clot retriever, a corkscrew-like device, and then more recently with approval of the Penumbra thromboaspiration system. Both devices are associated with a high rate of recanalization (total, partial, and complete). However, time to recanalization was on average 45 minutes, with a low rate of complete clot resolution, given that the majority of patients achieved only partial recanalization. More recently, retrievable stents have shown promise in reducing the time to recanalization, and they achieve a higher rate of complete clot resolution with improved feasibility. The retrievable stent can be opened within the clot to engage it within the stent struts, and subsequently it is retrieved by pulling it under flow arrest. The retrievable stents provide a new tool in the armamentarium of devices that can be used to achieve safe and timely clot removal. This review provides the historical evolution of endovascular therapy to use of stentreivers. Neurology ® 2012;79 (Suppl 1):S148-S157 GLOSSARY AIS ϭ acute ischemic stroke; CI ϭ confidence interval; ECASS ϭ European Cooperative Acute Stroke Study; FDA ϭ US Food and Drug Administration; IA ϭ intra-arterial; ICA ϭ internal carotid artery; ICH ϭ intracerebral hemorrhage; IMS ϭ Interventional Management of Stroke; MCA ϭ middle cerebral artery; mRS ϭ modified Rankin Scale; NIHSS ϭ NIH Stroke Scale; NINDS ϭ National Institute of Neurological Disorders and Stroke; OR ϭ odds ratio; PROACT ϭ Prolyse in Acute Cerebral Thromboembolism; RSs ϭ retrievable stents; rtPA ϭ recombinant tissue plasminogen activator; SESs ϭ self-expanding stents; SWIFT ‫؍‬ Solitaire FR With the Intention for Thrombectomy; TICI ϭ thrombolysis in cerebral ischemia; TIMI ϭ thrombolysis in myocardial infarction.
Acute ischemic stroke (AIS) therapy is based on the concept that early recanalization of the occluded artery leads to improved clinical outcome through preservation of the time-sensitive penumbra. [1] [2] [3] There has been an evolution in the development of techniques used to achieve faster and safer rates of recanalization. Because of the limited efficacy of pharmacologic thrombolysis, mechanical and multimodality methods have been sought to aid revascularization of the occluded artery. A newer endovascular approach using retrievable stents (RSs) shows promising results for better and faster rates of recanalization with possibly better shortterm outcomes. THE EARLY FOUNDATION OF STROKE THERAPY IV thrombolytic treatment with recombinant tissue plasminogen activator (rtPA), initiated within 3 hours from symptom onset, is the only medical therapy currently approved by the US Food and Drug Administration (FDA) for AIS. This approval was based on the results published in 1995 by the National Institute of Neurological Disorders and Stroke (NINDS) and rtPA Stroke Study Group trial. 4 The NINDS study group reported that compared with the placebo group, administration of rtPA to patients with AIS within 3 hours of symptom onset led to an overall 32% relative (12% absolute) increase in the proportion of patients with minimal or no disability at 3 months. 4 A subsequent analysis of the NINDS study 5 and a pooled analysis of 6 major randomized placebocontrolled IV rtPA stroke trials 3 showed an association of outcome with early stroke treatment. The combined analysis-Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) I and II, NINDS I and II, and European Cooperative Acute Stroke Study (ECASS) I and II-included 2,775 patients who were treated with IV rtPA or a placebo within 360 minutes of symptom onset. 3 The analysis confirmed the benefit of treatment up to 3 hours and further suggested a potential benefit beyond 3 hours for a certain subgroup of patients. In a narrower subgroup of patients, the benefit of IV rtPA 3 to 4.5 hours from onset of symptoms was later confirmed by the ECASS-III trial. 6 A Cochrane Database review analyzed 18 trials (16 of which were double-blinded) with a total of 5,727 patients who were treated with thrombolytics (streptokinase, rtPA, IV urokinase, or prourokinase) up to 6 hours after symptom onset; the analysis showed a significant reduction in death and dependency (modified Rankin Scale [mRS] score, 3-6) at the 3-to 6-month follow-up (odds ratio [OR] 0.84; 95% confidence interval [CI] 0.75-0.95). 7 This was in spite of a significant increase in the odds of death within the first 10 days (OR 1.81; 95% CI 1. 46 -2.24) . A separate Cochrane review that analyzed different doses, routes of administration, and agents used for thrombolysis in AIS confirmed that higher doses of thrombolytic therapy were associated with a 3-fold increase in fatal intracerebral hemorrhage (ICH). 8
Intra-arterial thrombolysis. Intra-arterial (IA) thrombolysis allows direct infusion of the fibrinolytic agent into the thrombus; thus, a smaller dose of drug can reach a higher local concentration than with an IV infusion. In theory, IA therapy could permit better rates of recanalization with reduced systemic complications and ICH, due to the smaller doses of thrombolytics used. IA thrombolysis gained validity on the basis of the results from 2 randomized trials and several case series. 9 -12 The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial 10 was a prospective randomized trial to test efficacy and safety of IA prourokinase plus heparin, vs heparin alone, in patients with occlusion of the middle cerebral artery (MCA) who could have initiation of treatment within 6 hours of symptom onset. Partial or complete recanalization was achieved in 67% of patients in the treatment group. Of the treated patients, 40% had an mRS score of 0 -2 at 90 days, compared with 25% of control subjects ( p ϭ 0.04). Complete restoration of blood flow (Thrombolysis In Myocardial Infarction [TIMI] 3) was achieved in 20%, and an additional 46% in the treatment group had partial recanalization (TIMI 2) vs only 20% with TIMI 2-3 in the control group. Symptomatic ICH occurred in 10% of patients within the treatment group, compared with 2% of control patients ( p ϭ 0.06). The FDA required a confirmatory study prior to approval. No placebo-controlled, randomized studies have tested the use of IA rtPA therapy in AIS.
Bridging therapy. It is understandable that there are inherent delays in performing endovascular procedures, which is why IV rtPA therapy remains firstline treatment. Unfortunately, IV rtPA achieves recanalization rates of only approximately 9% for occluded extracranial internal carotid arteries (ICAs) 13 and 28% to 30% for occlusions of the M1 segment of the MCA. 13, 14 Furthermore, early reocclusion occurs in 34% of patients treated with rtPA who had any initial recanalization. 14 Ideally, bridging therapy combines the rapidity of administration by the IV route with the better efficacy of the IA approach. The Interventional Management of Stroke (IMS) II study showed the feasibility and safety of a combined IV and IA treatment with rtPA. 15 The 81 subjects enrolled with NIH Stroke Scale (NIHSS) scores Ն10 had two-thirds the IV dose initiated within 3 hours of symptom onset, followed by IA thrombolysis. Previous studies evaluating the combined approach have shown better recanalization rates; however, they have shown only trends toward better outcomes, as compared with the IV rtPA-treated subjects in the NINDS rtPA Stroke Trial 15 or a database registry. 16 An additional study has shown the potential benefit of bridging therapy increases when the target population is limited to IV rtPA nonresponders (40% of IV-IA patients reached functional independence at 3 months, compared with 14.9% of IV nonresponders [ p ϭ 0.012]); however, the benefit came at the cost of a higher morbidity and mortality associated with the bridging therapy (OR 1.49 and 95% CI 0.70 -3.16 for death; OR 2.14 and 95% CI 0.58 -7.83 for symptomatic ICH). 17 The IMS III trial comparing IV and multimodal-approach IA therapy to IV rtPA only is currently underway.
Mechanical approaches to stroke therapy. The theoretical advantages of mechanical approaches include a reduced need for thrombolytics, faster rates of recanalization, and fragmentation of the thrombus, which increases the surface area accessible to the fibrinolytic agents. Early studies utilizing endovascular retrievers or aspiration devices did not show the anticipated rates of clinical improvement, despite achieving higher recanalization rates. 18, 19 Three uncontrolled trials have led to FDA approval of 2 devices, the Merci Retriever (in 2004) and the Penumbra System (in 2008), for the indication of intracranial clot retrieval in patients with AIS. The Merci clot retrieval device (Concentric Medical, Mountain View, CA) achieved 69.5% vessel recanalization (TIMI 2-3) with adjuvant IA rtPA. 19 The Penumbra thromboaspiration system (Penumbra, Inc., Alameda, CA) achieved an 81.6% recanalization rate (TIMI 2-3), though the ICH rate was 28% (11% symptomatic) within 24 hours of treatment. 18 Self-expanding stents. The limitations of the currently approved therapies have driven the pursuit of devices that can further expedite and improve the degree of flow restoration. Starting in 2006, reports in the literature indicated that varied combinations of angioplasty alone, balloon-mounted stents, and selfexpanding stents (SESs) were being utilized in the treatment of AIS. In a multicenter analysis of endovascular reperfusion therapies, in a cohort of 1,122 patients with AIS, stent deployment was an independent predictor of TIMI 2-3 recanalization (OR 1.91; 95% CI 1.23-2.96; p Ͻ 0.001). 20 Conceptually, the occlusive clot is rapidly displaced outwardly along the vessel wall and becomes entrapped in the interstices of an SES as it is completely or partially deployed.
Retrievable stents.
A completely deployed SES requires dual antiplatelet therapy, and in the acute setting IV glycoprotein IIb/IIIa inhibitors are often used. The additional risk of hemorrhagic complications from the combination of thrombolytics and glycoprotein IIb/IIIa inhibitors, as well as the long-term risk of in-stent stenosis, has brought about the concept of RSs. In the literature, restenosis and reocclusion rates of 25% and 32.3% for SESs used in atherosclerotic lesions have been reported. 21, 22 Also called stentrievers, RSs offer the advantage of immediate flow restoration after deployment and the ability to retrieve the stent after mechanical embolectomy. Some models of RSs allow permanent detachment for resistant lesions or underlying intracranial stenosis. In theory, an RS offers the rapidity of the SES to open the vessel, while maintaining navigability of the intracranial vessels and the capability of thrombus extraction, all the while diverting the long-term risks associated with SESs. Furthermore, RSs negate the longterm need for dual antiplatelet therapy and IV glycoprotein IIb/IIIa inhibitors in the acute setting (figure).
The safety and efficacy evaluation of RSs in animal models provided important technical data with clinical implications. Jahan 23 performed mechanical thrombectomy in swine. Successful TIMI 3 recanalization was achieved in all 6 cases within 1 to 2 passes with the Solitaire device (ev3 Inc., Irvine, CA). No distal embolization, vessel damage, or thrombosis was noted. Postprocedure vasospasm was encountered but resolved in all cases. Postprocedure angiography at 30 days showed no evidence of vessel damage. Microscopic examination of the treated vessels at 30 and 90 days showed mild intimal thickening with approximately 1% to 5% narrowing of the vessel lumen.
Several small case series utilizing the Solitaire device demonstrate recanalization (TIMI 2-3) rates from 88% to 90% following 1 or 2 passes with the device. 24 -27 One of the first reported case series of 20 subjects treated with the Solitaire device was published in 2010. 24 The device was used as rescue therapy in 2 patients refractory to IA rtPA and in 3 patients after unsuccessful recanalization with the Merci device. Following a mean of 1.4 passes, successful revascularization (Thrombolysis in Cerebral Ischemia [TICI] grade 2b or 3) was achieved in 90% of treated vessels, with a mean time to recanalization of 50 minutes and a symptomatic ICH rate of 10%. At the 90-day follow-up, 45% of patients had good functional outcome (mRS score Յ2), and the mortality rate was 20%. Similarly, in a second series of 26 patients with AIS who underwent Solitaire device-assisted thrombectomy, 42.3% had a favorable clinical outcome (mRS Յ2); the lowest rate was seen in patients with basilar artery occlusion (20%). 25 In addition, a series of 22 patients with AIS and ICA occlusions were treated with the Solitaire device, and successful revascularization was achieved in 90.9% of patients (TICI grade 2a/b in 36.3%; TICI grade 3 in 54.5%). 27 The mean time from stroke symptom onset to recanalization was 277 minutes. Fifty percent of patients showed favorable outcome at 90 days, and mortality was 18.1%. ICH occurred in 3 patients (2 symptomatic).
One of the larger reported studies with an RS was presented at the 2011 International Stroke Conference. 28, 29 Among the 89 subjects enrolled, 48% of the patients received rtPA prior to the intervention. The location of the thrombus was in the M1 segment in 44%, vertebrobasilar artery in 15%, ICA terminus in 14%, and ICA and MCA (tandem occlusions) in 14%. Both the Trevo (Concentric Medical, Mountain View, CA) and Solitaire systems were utilized in the study. Following a mean of 1.4 passes per patient, the average recanalization time was 45 minutes (27-60 minutes), and no case of technical failure was reported. The recanalization rate achieved was 91% (TIMI 2-3). ICH occurred in 11% of patients (9% symptomatic). Follow-up data at 90 days was available for 74 patients, and good clinical outcome (mRS Յ2) was achieved in 47%; mortality rate was 20%.
Results with the Trevo device were presented at the 2010 European Stroke Conference. 30 Thirty patients were enrolled, with a mean NIHSS score of 17.36. Recanalization (TIMI 2-3) was achieved in 93.3%; however, no ICH, clinical outcomes, or mor- is an open-label, randomized trial comparing the efficacy and safety of the Solitaire RS system with the Merci device. 31 The primary outcome is recanalization rate of an occluded target vessel to TIMI 2 or 3. Secondary outcomes are time to initial recanalization as well as NIHSS score, Barthel index, and mRS score at 30 and 90 days postprocedure. Morbidity and mortality rates and the incidence of symptomatic ICH are also recorded at these time points. The study includes patients with NIHSS scores of 8 -30 presenting within 8 hours of stroke symptom onset.
Patients included in the trial may be those who are ineligible for IV rtPA or whose IV rtPA failed before the procedure. The SWIFT study was halted by the data monitoring board in early 2011 after 126 patients of the anticipated 250 were enrolled. The company is currently seeking FDA approval based on the study results. Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke 2 (TREVO 2) is a nonrandomized, open-label trial evaluating the efficacy of the Trevo device in large-vessel occlusions in AIS patients. 32 The primary outcome is revascularization, defined as at least TICI 2a in the target vessel. The secondary outcomes are mRS score, NIHSS score, and mortality at 90 days. Device-related serious adverse events and symptomatic ICH rates are also recorded. The exclusion criteria are similar to those of the SWIFT trial, described previously. DISCUSSION Although the number of RSs for AIS therapy has been growing, none of the devices has gained FDA approval in the United States. The devices that are currently in clinical trials or being investigated include Solitaire FR, Trevo, Revive (Codman Neurovascular, San Jose, CA), Pulse (Penumbra, Inc., Alameda, CA), and Flow/Capture (MindFrame, Inc., Lake Forest, CA).
Since the development of these devices is relatively new, only a limited number of publications with small case series are available in the literature (table) . [23] [24] [25] [26] [27] [28] [29] [30] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] If we summarize the data from the studies listed in the table, the average recanalization rate is 93.3% to achieve a TICI 2-3/TIMI 2-3 score in a mean of 1.8 passes. Favorable outcome, as measured by mRS score of 0 -2, was achieved in 49.2% of patients at 90 days, with an average mortality rate of about 17.4%. The overall incidence of symptomatic intracranial hemorrhage was 6.7%, which is comparable to the rate of symptomatic intracranial hemorrhage in other clinical trials (10% in PRO-ACT II, 10 11% in the Penumbra trial, 18 and 9.8% in the Multi-MERCI trial 19 ). Reversible vasospasm and spontaneously detached stents were seen in a few cases; however, overall complication rates were low. It is difficult to evaluate the efficacy and safety of the RS alone in these small case series. In a significant number of cases, the RS was used in a multimodal approach, and in some cases the RS device was used as a salvage maneuver after other mechanical devices failed. Perhaps the overall mean duration of treatment of 67.4 minutes would improve if the RS was utilized as first-line treatment in IA therapy. Furthermore, lack of uniformity in primary and secondary outcome measures makes interpretation of the overall outcome difficult. CONCLUSION Multimodal combination therapies for AIS achieve faster and better rates of recanalization. Faster recanalization should result in improved outcome in AIS. [47] [48] [49] [50] Ideally, the optimal therapy should not only increase the likelihood of a favorable outcome but also reduce the likelihood of ICH. Currently, recanalization rates of endovascular treatment are around 67% for IA thrombolysis 10 and 68% to 81.6% for the combination of mechanical thrombectomy with IV and IA thrombolysis. 18, 19 An impetus for the endovascular field is to develop recanalization devices that safely exceed the efficacy of IV and IA pharmacologic therapy.
The available nonrandomized, uncontrolled data on RSs from case series show promising results with better and faster recanalization rates, possibly better short-term outcomes than with other reported endovascular devices, and mortality and ICH rates comparable with published results of previous neurointerventional studies. Larger clinical trials are ongoing to assess the advantages of RSs in AIS therapy. Perhaps FDA approval of such devices is looming in the near future.
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